How to access Daybue from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE family of a child, adolescent, or adult with Rett syndrome may receive a prescription for Daybue (trofinetide) from their treating paediatric neurologist. Daybue is FDA-approved as the first therapy specifically indicated for Rett syndrome, developed by Acadia Pharmaceuticals. Rett syndrome is a rare, progressive, X-linked neurodevelopmental disorder affecting primarily girls, with onset typically in early childhood. In the UAE, Daybue is not locally registered, which is why your paediatric neurologist will navigate the named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Daybue is a synthetic analogue of a naturally occurring tripeptide derived from insulin-like growth factor 1 (IGF-1), taken as an oral liquid twice daily dosed by weight. Eligibility is based on clinical diagnosis of Rett syndrome, typically supported by genetic confirmation of a pathogenic variant in MECP2, and ongoing management by a paediatric neurologist familiar with Rett syndrome. Your neurologist will confirm diagnosis, baseline function (using standardised Rett-specific scales), and set up monitoring. Daybue can cause diarrhoea and vomiting, so families are counselled on hydration and dose-adjustment strategies. Because Daybue is oral, in-country administration is straightforward once the prescribing plan is in place.
Is Daybue legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. For Rett syndrome in the UAE, there is no locally registered disease-specific alternative, making the clinical rationale straightforward.
How the pathway works, step by step
- Consultation with your treating paediatric neurologist. Clinical diagnosis of Rett syndrome with supporting MECP2 genetic confirmation, and a written clinical rationale.
- Baseline assessment. Weight, Rett-specific functional scales, GI tolerance baseline, and hydration plan are documented.
- MoHAP named-patient application. Your physician or hospital pharmacy files the application with clinical rationale, genetic report, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Daybue from authorised distribution.
- Shipment. Daybue ships with chain-of-custody documentation; a cold-chain handling requirement applies for portions of the supply chain per manufacturer instructions.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the family with weight-based dosing instructions and GI-symptom management guidance.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Rett syndrome diagnosis, MECP2 report, baseline function, and Daybue as the indicated treatment
- Verification of their UAE medical licence
- A copy of the MECP2 genetic diagnostic report
- Patient identifier (anonymised reference where possible)
- Planned dosing schedule based on weight, with a plan for dose adjustments as the child grows and for management of GI tolerability
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for rare-paediatric-neurology named-patient imports, including the GI-tolerability and hydration-management plan that is central to Daybue adherence.
Costs and timing
Daybue's US cash-pay reference cost is weight-dependent because dosing scales with body weight. Indicative 2026 annual cost sits in a broad range of roughly USD 375,000–575,000, with adult patients and larger adolescents at the higher end of that range. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling basis against your monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: Rett syndrome primarily affects girls and places long-term caregiving demands on mothers, aunts, and extended female family. Our concierge coordination is deliberately inclusive of whichever family members the primary caregiver designates — a mother in Abu Dhabi, an aunt in Sharjah, a sister in Europe — on refill logistics and care-coordination calls.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Daybue specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP review.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact for the family, coordinating long-term refills and weight-based dose adjustments as the child grows.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import for rare-paediatric-disease therapies is a recognised mechanism. See our trust and compliance page.
Is Daybue a cure? Daybue is a disease-modifying therapy intended to improve certain Rett-syndrome symptoms. Pivotal study endpoints focused on functional improvement. Your paediatric neurologist will discuss realistic outcome expectations.
How is GI tolerability managed? Diarrhoea and vomiting are recognised on-label effects. Your neurology team will advise on dose adjustment strategies, hydration planning, and anti-diarrhoeal supportive measures.
Can an adult with Rett syndrome receive Daybue? Yes — FDA labeling covers paediatric and adult patients. Your physician will advise on age- and weight-appropriate dosing.
Will insurance cover this? Cash-pay is the default. Some UAE insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Daybue coordination in the UAE.
Add me to the Daybue waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.